Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. 1988

B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
Department of Paediatrics, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.

Imipenem, a new N-formimidoyl thienamycin was given together with cilastatin to 20 patients with cystic fibrosis and pulmonary infection due to Pseudomonas aeruginosa. The antibiotic was given in short-term infusions for 9-14 days (mean 11.5) in a dose of 45-60 mg/kg body weight/day. Good clinical results were obtained in all patients with significant improvement of clinical score, pulse rate, vital capacity and FEV1.0 (P less than 0.001). Blood PO2 increased and WBC decreased significantly. A slight increase in the minimum inhibitory concentration was noted during treatment but all strains examined were fully susceptible at follow-up one month later. The peak serum concentration was significantly increased in patients receiving the high dose of imipenem, but the sputum concentration was low in all patients and there was no difference in clinical or bacteriological outcome. The plasma and urinary clearance increased with body weight and was inversely correlated to clinical score. Imipenem/cilastatin appears a good alternative for the treatment of pulmonary infections caused by P. aeruginosa in cystic fibrosis.

UI MeSH Term Description Entries
D008297 Male Males
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
November 1985, The Journal of antimicrobial chemotherapy,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
January 1987, The Journal of antimicrobial chemotherapy,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
January 1985, Reviews of infectious diseases,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
January 1990, La Pediatria medica e chirurgica : Medical and surgical pediatrics,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
April 1985, Antimicrobial agents and chemotherapy,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
November 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
April 1990, Presse medicale (Paris, France : 1983),
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
April 1988, The Journal of antimicrobial chemotherapy,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
July 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
B Strandvik, and A S Malmborg, and T Bergan, and H Michalsen, and O T Storrøsten, and B Wretlind
February 1993, Zeitschrift fur Gastroenterologie,
Copied contents to your clipboard!